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To the Editor:
We read with great interest the pa-
per from Kottenberg and colleagues,1TABLE 1. Results in metaregression and subgrou
Variables
No. of comparUnivariate analysis
b-blockers (%) (CABG only) 11
b-blockers (%) 14
Volatile agents 16
Multivariate analysis
b-blockers (%) 14
Volatile agents 14
Subgroup analysis
b-blockers (%) 14
>75% 5
75% 9
Volatile agents 15
Volatile 12
Nonvolatile 4
Original data from Zhou and associates.4 SMD, Standardize
The Journalrecently published online in the Jour-
nal. Building on their previous study,2
they have conducted 2 impressive
independent works to explore the car-
dioprotection by remote ischemic pre-
conditioning (RIPC) with isoflurane3
or propofol1 in coronary artery bypass
grafting (CABG).1-3
There has always been concern
regarding whether b-blockers could
interfere with the cardioprotective ef-
fect of RIPC. In their fundamental
study,2 the mean b-blocker usage rates
were 60% in the propofol substudy
and 64% in the isoflurane substudy,p analyses
isons
Coefficient or SMD
95%Coefficient
0.0258 0.0052 to
0.0161 0.0028–0
0.6617 0.0481 to
Coefficient
0.0129 0.00234 t
0.4037 0.5019 to
SMD
0.28 0.61 to
0.18 0.26 to
0.56 0.96 to
0.28 0.57 to
0.11 0.41 to
0.81 1.28 to
d mean difference; CI, confidence interval; CABG, coronary
of Thoracic and Cardiovascular Surgerand a better preservation of RIPC-
induced cardioprotection with isoflur-
ane than propofol was proposed. This
difference seems to remain unchanged
in the population, however, with
higher proportion of b-blocker medi-
cation (83% in propofol1 group and
87% in isoflurane).3 Their series of
studies indicates that the anesthetic
choice is more critical than b-blocker
use in the interference of cardiopro-
tection by RIPC.
Nevertheless, our group’s recent
meta-analysis,4 which included 15
randomized, controlled trials withCI P value
Adjusted R2 or
PDifference value
Adjusted R2
0.0567 .092 0.22
.0295 .022 0.37
1.3716 .065 0.23
Adjusted R2
o 0.0282 .089 0.38
1.3092 .348
PDifference value
0.04 .09 .02
0.61 .43
0.16 .006
0.02 .06 .01
0.19 .46
0.34 .0008
artery bypass grafting.
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Letters to the Editor1155 adult patients undergoing car-
diac surgery, found that both b-
blockers and volatile anesthetics are
potentially influential factors in cardi-
oprotection by RIPC, a finding
confirmed in univariate metaregres-
sion and subgroup analyses. The role
of b-blockers remained significant in
the CABG subgroup (Figure 1). In
addition, the potential interference of
b-blockers was independent of vola-
tile anesthetics in the subsequent
multivariate analysis (Table 1). More-
over, previous studies that used animal
hearts or human isolated atrial trabec-
ulae have suggested that b-blockers
could abolish the cardioprotection of
ischemic or anesthetic precondition-
ing (see discussion in reference 4). In
addition, no cardiac benefit from
RIPC in CABG was observed in Luc-
chinetti and associates’ study,5 which
had a mean b-blocker proportion of
91%. These evidence suggested
greater significance of b-blockers in
the cardioprotective effect of RIPC,
which is thusmore important in the po-
tential interference with cardioprotec-
tion by RIPC.
Is it b-blockers or anesthetic
choice? The findings from my group
are based mainly on the aggregate
patient data. We are therefore inter-
ested to know whether this would
hold true for the individual patient
data in Kottenberg and colleagues’
study2 if multivariate linear regres-
sion analyses at least including
b-blockers and anesthetic choice
in a total of 72 patients were
performed.
Yang Liu, MDa
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THE AMERICAN COLLEGE OF
SURGERY ONCOLOGY GROUP
Z0030 TRIAL
To the Editor:
We read with great interest the report
by Darling and colleagues1 regarding
the impact onpatient survival ofmedias-
tinal lymph node dissection (MLND)
during lung cancer surgery. This study
focused strictly on whether MLND had
any impact on survival relative to reli-
able mediastinal lymph node sampling.
This is oneof themost challengingques-
tions in thoracic surgery; to answer
it, Darling and colleagues1 prepared
and executed an elaborate protocol.
Although the result was negative—that
is, MLND did not show any survival
benefit relative to mediastinal lymph
node sampling—the data acquired
from this studyare of great clinical value
for benchmarking. Whereas this study
was carried out by authorized expert
thoracic surgeons, our real-world prac-
tice can be assessed by comparing our
results with the published outcomes of
morbidity and mortality.2
Darling and colleagues1 reported
285 recurrences, including 54 local,Cardiovascular Surgery c November 2074 regional, and 225 distant recur-
rences, in the eligible subject popula-
tion. Although it is unclear whether
each recurrence number was counted
by case or site, we are very interested
in the definition of the terms, namely,
local, regional, and distant recurrence.
Because the local and regional recur-
rence rates vary according to the de-
finition of the terms3 and a standard
definition does not currently exist, we
would like investigators to specify their
definitions of these terms. Several loca-
tions should be considered as the recur-
rence sites in the definition, including
bronchial stump, ipsilateral hilum, in-
terlobar staple line, ipsilateral medi-
astinal lymph node, ipsilateral lung
parenchyma, ipsilateral thoracic cavity
(pleural dissemination and malignant
pleural effusion), contralateral medias-
tinal/hilum lymph node, supraclavicu-
lar lymph node, contralateral lung
parenchyma, chest wall, and malignant
pericardial effusion.We hope that stan-
dard definitions for recurrence siteswill
be established in the near future.
The American College of Surgery
Oncology Group Z0030 trial results
continue to produce new findings.4
We believe the full utilization of this
landmark database is important to
improve clinical practice and future
studies.
Hideo Ichimura, MD
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